# Caris Life Sciences share price today (Caris Life Sciences, Inc., CAI)

> Caris Life Sciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CAI · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/cai

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $26.03 (+1.6% in a year)
- P/E: 78.1×, against its own history
- Revenue (Jun 2026): $264 M (+45.4% on a year ago)
- Profit (Jun 2026): −$637 K
- Operating margin: 10.2% (+20.1 points on a year ago)
- ROE: −93%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Caris Life Sciences share price today? Caris Life Sciences, Inc.'s share price was $26.03 at the close on 5 November 2026. It has been stalling near its high for 1 week. That is 20.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $15 and $34, and at that close it sat 58% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. Over the last 1 year the share price moved −4% while the S&P 500 moved +23%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Caris Life Sciences pay? Caris Life Sciences, Inc. pays no dividend. In the last 10 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Caris Life Sciences on? Caris Life Sciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Caris Life Sciences profitable? Caris Life Sciences, Inc. posted a net loss of $637 K in the Jun 2026 quarter. The full FY25 year was a loss of $538 M. That loss is 0.2% of the quarter's revenue. The same quarter a year earlier lost $517 M. 8 of the last 10 reported quarters were loss-making. ## How much revenue does Caris Life Sciences make, and is it growing? Caris Life Sciences, Inc. reported $264 M of revenue in the Jun 2026 quarter, +45.4% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 3 years it has grown 46.5% a year on average. The last full year, FY25, came in at $812 M. The last four reported quarters add to $990 M. FY25 revenue was $812 M, +97.0% on the year before. Recent pace: the last four quarters grew +90.8% on average, against 46.5% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every $100 of sales does Caris Life Sciences keep? Caris Life Sciences, Inc.'s operating margin was 10.2% in the Jun 2026 quarter, 20.1 percentage points higher than the same quarter a year ago. Across 4 years it has been between −122.2% and 5.6%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +20.1 percentage points on the year while gross margin changed +5.4 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Caris Life Sciences' profit turning into cash? Caris Life Sciences, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $83.2 M of operating cash against −$538 M of profit. After $16.3 M of spending on assets, $66.9 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Caris Life Sciences' cash go? Caris Life Sciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $47.0 M on assets over the last 3 years. Averaged over those years that is 1.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $47.0 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Caris Life Sciences' P/E ratio, and how does it compare with its own history? Caris Life Sciences, Inc.'s P/E is 78.1×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Caris Life Sciences business getting better or worse? Caris Life Sciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Caris Life Sciences earn on its capital? Caris Life Sciences, Inc. earned a ROE of −93% in FY25. That is up from a low of −159% in FY22. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −66.2% net margin and 0.72× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −66.2% net margin × 0.72× asset turnover × 1.95× leverage (assets divided by equity) ≈ −92.9% on equity. The margin does its share; borrowing is a big part of it. ## Does Caris Life Sciences have too much debt? Caris Life Sciences, Inc. has total debt of $452 M against shareholder equity of $592 M as of Jun 2026, so its debt is 0.76× its equity. Year by year, that ratio went from 1.07 in FY22 to 0.74 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Caris Life Sciences shareholding pattern? 10.1% of Caris Life Sciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 2.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Caris Life Sciences from balance-sheet trouble? For Caris Life Sciences, Inc., the Z-score is 5.47. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.47 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Caris Life Sciences rank in its industry? There is no score against its industry: Caris Life Sciences, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Caris Life Sciences compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Caris Life Sciences in size? Caris Life Sciences is the 34th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Corcept Therapeutics Incorporated, Cytokinetics, Incorporated and ABIVAX Société Anonyme. Just below it: Praxis Precision Medicines, Inc., Rhythm Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. ### Biotechnology companies close in size

1. [Corcept Therapeutics Incorporated](https://www.sectoralpha.in/us/stocks/cort) $7.8 billion
2. [Cytokinetics, Incorporated](https://www.sectoralpha.in/us/stocks/cytk) $7.7 billion
3. [ABIVAX Société Anonyme](https://www.sectoralpha.in/us/stocks/abvx) $7.6 billion
4. Caris Life Sciences, Inc. $7.5 billion
5. [Praxis Precision Medicines, Inc.](https://www.sectoralpha.in/us/stocks/prax) $7.3 billion
6. [Rhythm Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rytm) $7.3 billion
7. [Axsome Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/axsm) $6.8 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Chewy, Inc.](https://www.sectoralpha.in/us/stocks/chwy) $9.4 billion · Internet Retail
2. [Old Republic International Corporation](https://www.sectoralpha.in/us/stocks/ori) $9.4 billion · Insurance - Property & Casualty
3. Caris Life Sciences, Inc. $9.4 billion
4. [Nova Ltd.](https://www.sectoralpha.in/us/stocks/nvmi) $9.4 billion · Semiconductor Equipment & Materials
5. [Antero Midstream Corporation](https://www.sectoralpha.in/us/stocks/am) $9.4 billion · Oil & Gas Midstream

## What else do people ask about Caris Life Sciences? ### What were Caris Life Sciences's latest quarterly results? Caris Life Sciences, Inc. reported revenue of $264 M and a net loss of $637 K for the Jun 2026 quarter. Earnings per share were $0.00. The operating margin was 10.2%, 20.1 percentage points higher than a year earlier (as of 5 November 2026). ### What is Caris Life Sciences's market cap? Caris Life Sciences, Inc.'s market capitalisation is $7.5 B at a stock price of $26.03. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Caris Life Sciences performing? Caris Life Sciences, Inc.'s share price has been stalling near its high for 1 weeks. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Caris Life Sciences's stock price go up? This page does not forecast Caris Life Sciences, Inc.'s stock price. What it shows instead: the stock price is $26.03, and it has been stalling near its high for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Caris Life Sciences in its business cycle? Caris Life Sciences, Inc.'s FY25 operating margin was 5.6%, against a 4-year range of −122.2% to 5.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 10.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Caris Life Sciences story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Caris Life Sciences a stock worth studying right now? What the numbers show: Caris Life Sciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.